Exploring Zomedica Corp. (ZOM) Investor Profile: Who’s Buying and Why?

Have you ever wondered who's investing in Zomedica Corp. (ZOM) and, more importantly, why? As of December 30, 2024, a mix of institutional, retail, and individual investors make up Zomedica's shareholders. Institutional investors hold approximately 11.04% of the company's stock, while insiders own about 1.74%, and public companies and individual investors hold the remaining 87.21%. With Vanguard Group Inc being one of the largest shareholders, holding 4.91% of the shares, it's crucial to understand the motivations and strategies behind these investment decisions, especially with Zomedica's revenue reaching $27.3 million in 2024, an 8% year-over-year increase. Let's delve into the profiles of these key players and explore what makes Zomedica an attractive prospect in the veterinary health sector.

Zomedica Corp. (ZOM) Who Invests in [Company Name] and Why?

Understanding the investor profile of Zomedica Corp. (ZOM) provides valuable insights into the market's perception of the company and its future prospects. Zomedica, a veterinary health company, attracts a diverse range of investors, each with their own motivations and strategies.

Key Investor Types

The ownership structure of Zomedica Pharmaceuticals (ZOM) stock includes a mix of:

• Retail Investors: A significant portion of Zomedica's stock is held by retail investors. According to TipRanks data, retail investors hold approximately 87.21% of the company's stock.
• Institutional Investors: These include entities like mutual funds, hedge funds, and other institutions. Fintel states that Zomedica Corp. has 103 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 92,101,384 shares.
• Insiders: These are the company's executives and board members. TipRanks data indicates that approximately 1.74% of the company's stock is held by insiders.

Major shareholders among institutional investors include:

• Vanguard Group Inc
• VTSMX - Vanguard Total Stock Market Index Fund Investor Shares
• VEXMX - Vanguard Extended Market Index Fund Investor Shares
• Geode Capital Management, Llc
• BlackRock, Inc.
• FSMAX - Fidelity Extended Market Index Fund
• Renaissance Technologies Llc
• UBS Group AG
• State Street Corp
• Brown Brothers Harriman & Co

Investment Motivations

Several factors attract investors to Zomedica Corp.:

• Growth Prospects: Zomedica is seen as a growth company in the veterinary health industry, particularly with its strategic acquisitions and product diversification.
• Product Innovation: The company focuses on developing and commercializing innovative diagnostic and therapeutic products for companion animals.
• Market Position: Zomedica aims to address the unmet needs of clinical veterinarians, offering products that improve the quality of care for pets and the workflow, cash flow, and profitability of veterinary practices.
• Strategic Acquisitions: Zomedica has expanded its offerings through acquisitions, enhancing its product lines in therapeutic devices and diagnostics.
• Strong Financial Performance: Zomedica's financial performance underscores its growth potential, with recent reports indicating strong sequential and year-over-year increases.
• Improved Gross Margins: Investments in manufacturing have improved gross margins, situating the company at the high end of industry standards.

Investment Strategies

Investors in Zomedica employ various strategies:

• Long-Term Holding: Some institutional investors, like Vanguard and BlackRock, typically hold shares for the long term, reflecting confidence in the company's long-term potential.
• Short-Term Trading: Given the stock's volatility, some investors might engage in short-term trading to capitalize on price fluctuations.
• Value Investing: Some investors may view Zomedica as undervalued, especially considering its assets and growth opportunities. Alpha Spread estimates the intrinsic value of one ZOM stock under the Base Case scenario is $0.147 USD.

Additional factors influencing investor behavior:

• Analyst Ratings: Analyst ratings can influence investor sentiment. For example, Robert LeBoyer from Noble Financial initiated a Buy rating on Zomedica, which may attract more investors.
• Insider Transactions: Insider buying, such as Jeffrey Rowe's purchase of $96,098 worth of stock, can signal confidence in the company's prospects.
• Company Performance: Positive financial results, such as the $27.3 million revenue for the full year 2024, can attract investors.

Financial Overview

Key financial data from 2024 includes:

• Revenue: $27.3 million for 2024, an increase of 8% compared to 2023.
• Gross Margin: 70.0% for 2024.
• Liquidity: $71.4 million in cash, cash equivalents, and available-for-sale securities as of December 31, 2024.

Challenges and Delisting

Despite positive fundamentals, Zomedica has faced challenges, including:

• Price Weakness: A decline in stock price led to delisting from the NYSE American exchange.
• Transition to OTCQB: Zomedica's shares began trading on the OTCQB Venture Market under the symbol ZOMDF.

For further insights into Zomedica's financial health, you can refer to: Breaking Down Zomedica Corp. (ZOM) Financial Health: Key Insights for Investors

Revenue Forecast

Zomedica Corp. (ZOM) Institutional Ownership and Major Shareholders of Zomedica Corp. (ZOM)

Institutional ownership in Zomedica Corp. (ZOM) provides insights into the confidence and influence that large financial entities have in the company's stock. Examining the major shareholders and their recent activities can help investors understand the potential stability and strategic direction of the company.

As of the latest available data, several institutional investors hold significant positions in Zomedica Corp. (ZOM). While specific updated shareholding percentages can fluctuate, prominent institutional holders often include investment firms, hedge funds, and pension funds. These entities conduct thorough research before investing, and their collective decisions can impact Zomedica Corp. (ZOM)'s stock performance.

Changes in institutional ownership can signal shifts in sentiment towards Zomedica Corp. (ZOM). Increases in holdings may indicate a positive outlook, while decreases could suggest concerns about the company's future prospects. Monitoring these changes can provide valuable context for investors.

The presence of large institutional investors can influence Zomedica Corp. (ZOM)'s stock price through the volume of their trades. Additionally, these investors may engage with the company's management to advocate for specific strategies or governance practices, thereby playing a role in the company's overall direction. Keep in mind that investment information is dynamic and subject to change. For more insights into Zomedica Corp. (ZOM)'s financial standing, check out: Breaking Down Zomedica Corp. (ZOM) Financial Health: Key Insights for Investors

Zomedica Corp. (ZOM) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Zomedica Corp. (ZOM) provides valuable insights into the company's stability, strategic direction, and potential stock movements. As of April 2025, a mix of institutional, retail, and insider ownership characterizes Zomedica Corp. (ZOM).

According to recent data, 103 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 92,101,384 shares. While different sources present slightly varying figures, they consistently highlight the presence of significant institutional investment.

Here's a breakdown of the major types of investors:

• Institutional Investors: These include mutual funds, hedge funds, and other financial institutions.
• Retail Investors: These are individual investors who buy and sell shares for their own accounts.
• Insiders: These are the company's executives, directors, and other employees who own shares of Zomedica Corp. (ZOM).

According to Zomedica Corp. (ZOM): History, Ownership, Mission, How It Works & Makes Money, Zomedica Corp. features a mixed ownership structure, encompassing public shareholders, institutional investors, and potentially company insiders.

Notable Investors

Key institutional investors in Zomedica Corp. (ZOM) include:

• Vanguard Group Inc: Holding a significant number of shares across its various funds.
• BlackRock, Inc: Another major institutional investor with a substantial stake in the company.
• Geode Capital Management, Llc: This firm also holds a notable position in Zomedica Corp. (ZOM).
• Renaissance Technologies Llc: Holds a significant number of shares.

These major shareholders can exert influence on the company's decisions and stock performance.

Investor Influence

The ownership structure significantly impacts a publicly traded company like Zomedica Corp. (ZOM). Large institutional investors can influence management decisions through their voting power and can also affect the stock price through large-volume trading.

Specifically:

• Decision Making: Large institutional investors can influence company strategy and executive compensation.
• Stock Price: Substantial buying or selling by major shareholders can lead to price fluctuations.
• Company Stability: A strong base of long-term institutional investors can provide stability.

Recent Moves

Recent data indicates some shifts in institutional ownership. For example, Jane Street Group LLC, Northern Trust Corp, and Wells Fargo & Company MN increased their positions in Zomedica Corp. (ZOM) as of February 2025. Conversely, Virtu Financial LLC showed highly variable activity, significantly increasing its position earlier in 2024.

Here is a summary of institutional buying and selling activity:

These changes reflect ongoing evaluations of Zomedica Corp. (ZOM)'s potential and market conditions.

On March 4, 2025, Zomedica Corp. (ZOM) transitioned to the OTCQB Venture Market under the ticker symbol 'ZOMDF'. This move was due to not meeting the listing requirements of the NYSE American. Despite the change in trading venue, the company's CEO, Larry Heaton, assured that the company's asset value and growth opportunities remain intact.

As of March 4, 2025, the share price was $0.10, with a market capitalization of $95.35 million.

Zomedica Corp. (ZOM) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating the potential of Zomedica Corp. (ZOM). This involves analyzing the opinions of major shareholders, how the stock market responds to significant investor actions, and insights from analysts.

Here's a breakdown of key aspects:

• Major Shareholders: Institutions hold a significant portion of Zomedica's shares. According to recent filings, institutions hold a total of 92,101,384 shares. Top institutional holders include Vanguard Group Inc, Geode Capital Management, and BlackRock, Inc.
• Institutional Ownership: As of March 4, 2025, the share price was $0.10. On April 17, 2024, it was $0.13, marking a 25.33% decline.
• Fund Sentiment Score: This score reflects the degree to which funds are accumulating the stock, with higher numbers indicating greater accumulation.

Institutional ownership structure reveals current positions in the company by institutions and funds, along with recent changes in position size. Major shareholders include individual investors, mutual funds, hedge funds, or institutions. Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%.

To delve deeper into Zomedica's core values, explore: Mission Statement, Vision, & Core Values of Zomedica Corp. (ZOM).

Analyzing the put/call ratio provides insights into institutional sentiment. Put options generally indicate negative sentiment, while call options suggest positive sentiment.

Recent market reactions show how the stock market has responded to changes in ownership or large investor moves:

• Post-Earnings Surge: Following the release of Q4 2024 earnings, Zomedica's stock price increased by 17.9%, closing at $0.0975.
• Positive Investor Sentiment: The stock surge reflected investor confidence in the company's performance and strategic direction.
• Undervalued Stock: InvestingPro's Fair Value analysis suggests the stock is currently undervalued, although the RSI indicates it's in oversold territory.

Zomedica's Q4 2024 earnings highlighted an 8% year-over-year revenue growth. The company's strategic focus on the veterinary and equine markets contributed to this growth, despite InvestingPro data showing a 5-year revenue CAGR of 33%. With an EBITDA of $246.5 million and an EV/EBITDA ratio of 20.2x, Zomedica's position in shockwave therapy and point-of-care diagnostics is strong within the growing veterinary industry.

Financial highlights from the Q4 2024 earnings report include:

• Revenue: $7.9 million (8% year-over-year growth)
• Full Year 2024 Revenue: $27.3 million (record year)
• Gross Margin: 88.2%
• Net Loss: $7.2 million ($0.01 per share)
• Cash Position: $71.4 million

Analyst perspectives on key investors and Zomedica's future provide additional insights:

• Dawson James: Initiated a 'Buy' rating on January 6, 2023.
• HC Wainwright & Co.: Maintained a 'Buy' rating in multiple reports.
• Noble Capital Markets: Noted that Zomedica met product goals in 2024, with TRUFORMA assays driving sales growth.

Recent developments indicate both challenges and opportunities for Zomedica. The company's stock recently fell below $0.10 per share, leading to delisting from the NYSE American exchange and a move to the OTCQB Venture Market under the symbol ZOMDF. Despite this, Zomedica's CFO, Jordan Scott, purchased 300,000 shares of the company's common stock at $0.062 each, totaling an investment of $18,600, signaling confidence in the company's future.

The company's fundamentals are being undervalued by investors, suggesting the market may be underestimating its potential. The average one-year price target for Zomedica is $0.26, with forecasts ranging from $0.25 to $0.26.

Here's a snapshot of Zomedica's major shareholders and their recent activity:

Overall, analyst sentiment appears cautiously optimistic, with some analysts giving Zomedica a 'Buy' rating and projecting revenue growth. However, investors should be aware of the risks and conduct their own thorough analysis before making any investment decisions.

Zomedica's stock is currently in a holding pattern as investors await changes to the company's fundamentals and a clearer direction. As R&D costs ease and revenue channels expand, there is potential for growth, but convincing investors remains a long journey.